December 22, 2012
$PVCT: My Imaginary Conversation With $PFE's Dr. Craig Eagle
Dr. Eagle: That is not the right question to ask.
Me: What question should I ask?
Dr. E: Please continue.
Me: What do you think about PV-10?
Dr. E: It is unique.
Me: What more do you need before Pfizer will acquire the company?
Dr. E: The more data I have the better I can properly assess the drug's potential value when it is commercialized.
Me: Is Moffitt human data the final data you need?
Dr. E: Human Moffitt data is no more important than properly run non-clinical studies at Moffitt.
Me: What more data do you need?
Dr. E: What is most important to me is more data, in general. But, there already might be enough data.
Me: What would you pay for Provectus today?
Dr. E: I don't believe the conversation would be relevant to approach that way at this time.
Dr. E: This is the right answer until I am forced to say something different, which means someone else is prepared to outbid me or I am forced now by the better understanding of the exit (i.e., the approval path of PV-10 by the FDA).
Me: Thank you Dr. Eagle.